Plasmodium falciparum CS C-terminal fragment: Preclinical evaluation and Phase I clinical studies

Parassitologia

Volumn 41, Issue 1-3, 1999, Pages 421-424

  Roggero, M A ^a,d   Weilenmann, C ^b   Bonelo, A ^a,c   Audran, R ^a   Renggli, J ^a   Spertini, F ^b   Corradin, G ^a   Lopez J A ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d Dictagene   (Switzerland)

Author keywords

Human trial; Immune response; Malaria; Peptide; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; MALARIA VACCINE; PARASITE ANTIGEN; PEPTIDE FRAGMENT; PROTOZOAL PROTEIN;

ADULT; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; MOUSE; PHASE 1 CLINICAL TRIAL; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; REVIEW;

ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CLINICAL TRIALS, PHASE I; HUMANS; MALARIA VACCINES; MICE; PEPTIDE FRAGMENTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 0033181711     PISSN: 00482951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Blum-Tirouvanziam U, Beghdadi-Rais C, Roggero MA, Valmori D, Bertholet S, Bron C, Fasel N, Corradin G (1994). Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides J Immunol 153 4134-4141.
2. Blum-Tirotivanziam U, Servis C, Habluetzel A, Valmori D, Men Y, Esposito F, Del Nero L, Holmes N, Fasel N, Corradin G (1995) Localization of HLA-A2.1 restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum J Immunol 154: 3922-3931.
3. Chen DH, Tigelar RE, Weinbaum FI (1977) Immunity to sporozoite-induced malaria infection in mice. I. The effect of immunization of T and B deficient mice. J Immunol 118: 1322-1327.
4. López JA, González JM, Tolle R, Renggli J, Eberl G, Betschart B, Bujard H, Doumbo O, Arévalo M, Herrera S, Corradin G, Roggero MA (1995). Immunogenicity of synthetic peptides corresponding to the non-repeat regions of the Plasmodium falciparum circumsporozoite protein Vaccines 96 Cold Spring Harbor Laboratories, Cold Spring Harbor, USA
5. López JA, Roggero MA, Doumbo O, Gonzalez JM, Tolle R, Koita O, Arévalo-Herrera M, Herrera S, Corradin G (1996) Recognition of synthetic 104-mer and 102-mer peptides corresponding to the N-and C-terminal non-repeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors Am J Trop Med Hyg 55: 424-429
6. López JA, Gonzalez JM, Kettner A, Arévalo-Herrera M, Herrera S, Corradin G, Roggero MA (1997) Synthetic peptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum recognition by human T-cells and immunogenicity in Aotus monkeys Ann Trop Med Parasitol 91 253-265
7. Nussenzweig V, Nussenzweig RS (1989) Rationale for the development of an engineered sporozoite malaria vaccine Adv Immunol 45 283-334.
8. Roggero MA, Filippi B, Church P, Hoffman SL, Blum-Tirouvanziam U, Esposito F, López JA, Matile LH, Reymond CD, Fasel N, Corradin G (1995). Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N-and C-terminal regions of the Plasmodium falciparum CS protein. Mol Immunol 32: 1301-1309.